Stay informed about health and medicine news every weekday by subscribing to STAT’s free newsletter Morning Rounds. Sign up here.
As I sit down to write this article on a Thursday afternoon, I can’t help but be intrigued by Sarah Todd’s captivating story on the connections between Big Tobacco and Big Food. The opening is truly delightful, and I can’t wait to delve into the details. Scroll down to find out more.
TrumpRx Launches
President Trump’s new platform, aimed at reducing prescription drug prices, was unveiled yesterday after much anticipation. The impact it will have on affordability remains a topic of debate among experts.
The website, powered by technology from GoodRx, displays cash prices for certain medications, offering transparency for consumers. While the direct-pay model has been gaining popularity in the pharmaceutical industry, experts caution that purchasing drugs without insurance could potentially be more costly in the long run.
For a comprehensive overview of TrumpRx, including details on availability, pricing, and implications for consumers, check out the full article here.
Hospitals Cease Gender-Affirming Care for Minors
Over the past year, more than 40 hospitals and health systems have halted or paused gender-affirming care for young transgender individuals. This trend has accelerated in recent weeks following proposed federal regulations that threaten to withhold funding from clinics providing pediatric care for transgender youth.
Despite the uncertainty surrounding the finalization of the CMS rules and legal challenges to Trump’s executive order, hospitals are discontinuing services that have been vital for trans adolescents. Advocates argue that denying access to estrogen, testosterone, and puberty blockers could have detrimental effects on this vulnerable population.
For more insights into this concerning development, read STAT’s Theresa Gaffney’s in-depth report here.
Caution Advised for Multi-Cancer Early Detection Tests
During the upcoming Super Bowl, viewers may come across Hims’ latest commercial featuring Galleri, a multi-cancer early detection test. Despite not yet receiving FDA approval, telehealth platforms continue to promote these tests, raising concerns among cancer experts.
Grail, the developer of Galleri, has faced challenges in validating its blood-based test for detecting various tumor types. While a positive result may be accurate, studies have shown that the test can also miss cancers, leading to potential false reassurance for patients.
For a detailed analysis of the risks associated with multi-cancer early detection tests, refer to STAT’s Katie Palmer’s informative piece here.
Battle Against Ultra-Processed Food Mirrors Anti-Tobacco Campaign
Opponents of ultra-processed food are drawing parallels with the tobacco industry’s controversial history, suggesting that strategies used against Big Tobacco could be applied to combat the harmful effects of processed foods. Researchers, nutrition advocates, and policymakers argue that these products have exploited the brain’s reward system, leading to widespread health issues.
While the food industry denies these claims and emphasizes the convenience and safety of their products, critics continue to push for greater awareness of the health risks associated with ultra-processed foods. STAT’s Sarah Todd delves into this comparison between Big Tobacco and Big Food in her enlightening article here.
Decoding ‘Natural’ Dyes
The FDA recently announced a shift towards allowing companies to transition from artificial colors to dyes derived from natural sources. This change in labeling focuses on whether a dye originates from natural or petroleum-based sources, rather than whether it naturally occurs in the food it colors.
While some critics view this move as a step back from banning synthetic food dyes, it’s essential to understand that the term “natural” doesn’t always equate to being directly extracted from plants. The FDA’s new definition includes dyes produced through fermentation, chemical reactions, or breeding plants for enhanced color production.
For a deeper dive into the world of natural dyes and their implications, STAT’s Brittany Trang offers valuable insights here.
Former FDA Head Criticizes HHS Leadership
Former FDA Commissioner Robert M. Califf raises concerns about the undermining of evidence-based policy by current HHS leadership. Citing instances where individual opinions supersede scientific consensus, Califf emphasizes the importance of collective evidence in guiding public health decisions.
Highlighting the necessity of evidence-based healthcare, Califf warns against disregarding established expertise and data in favor of personal observations. He stresses the need for a solid foundation of evidence to ensure the safety and well-being of society.
To explore Califf’s viewpoint on evidence-based policy in healthcare, read the full article here.
Recommended Reads
-
Why are some women treating pregnancy like a marathon? WIRED
- Public Health Service officers in detention centers experience ‘moral distress’, NPR
- Exploring near-death experiences and what lies beyond, The Washington Post
- Measles outbreak in Mexico prompts health alert in World Cup host Jalisco, AP
-
Unlicensed weight-loss drugs promoted on social media as ‘prizes’, The Guardian
